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Abstract
Background: Diarrhea is one of the most common disorders in infancy and childhood and recurrent vomiting is a main reason for
hospitalization for these patients. This study was to assess the effect of injective ondansetron on decreasing the hospitalization rate
in children with diarrhea and recurrent vomiting.
Methods: In this clinical trial study, patients between six months and six years, with acute viral diarrhea and recurrent vomiting,
were assessed for the possibility of being treated as outpatients, based on their response to ondansetron, compared to a control
group who did not receive ondansetron. The sample size was 100 for each group. Cases for the ondansetron group were under
observation for at least two hours in the emergency ward and were followed until 72 hours to find out if there was any need for
them to return to the hospital due to vomiting. Otherwise, all cases in the control group were hospitalized. Data of both groups,
including the rate and duration of hospitalization, was analyzed.
Results: Of the 100 individuals who received ondansetron (n = 91) 91% did not need to be hospitalized and 9 patients needed to be
admitted in the next 72 hours, while (n = 100) 100% of control group were hospitalized (P value = 0.003). Vomiting in the control
group continued in 35% of patients after 72 hours of admission. The duration of hospitalization for the patients of the control group
was 2.94± 1.40 (mean± SD) days.
Interpretation: Ondansetron can be considered as an effective agent to decrease the hospitalization rate in infants and children
with diarrhea as well as vomiting. Injective forms of ondansetron seem to be more achieved than oral forms.
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1. Introduction
Diarrhea is one of the most common disorders in child-
hood. The world health organization (WHO) and UNICEF
estimate that almost 2.5 billion episodes of diarrhea occur
annually in children under 5 years of age in developing
countries. The overall incidence of diarrhea is about 3.6
episodes per child a year and it is estimated to account for
13% of all childhood disability adjusted life years (DALYs)
(1). Since recurrent vomiting is one of main reasons for ad-
mission of infants and children with gastroenteritis (GE)
in hospitals, control of vomiting in these patients can de-
crease the rate of hospitalization and lead to oral rehydra-
tion therapy (ORT), which is the preferred method for re-
hydration of the patients and is also endorsed by WHO and
other major health organizations (2). Rather than medical
benefits of treatment of GE patients as outpatient cases at
home, there are many socioeconomic advantages for the
family and community, due to not admitting a child or in-
fant into a hospital. Heavy costs of hospitalization, with
the fact that a large number of people are not under insur-
ance coverage in Iran, it is necessary to have a person ac-
companying the child/infant during their hospitalization
period. However, this may lead to other problems such as
when the parent or guardian is employed or has a problem
caring for other children at home etc. Also, some problems
related to health care systems, such as increased hospi-
tal occupancy, deficiencies in nurses and not enough hos-
pital equipment are some of problems due to high rates
of hospitalization for children and infants with diarrhea
and vomiting. In addition, drugs-related adverse events
predominate in academic pediatric centers, with children
aged more than 1 year to 5 years (3). Freedman et al., in their
conducted cost analysis study in USA and Canada, found
out that routine administration of ondansetron to eligi-
ble children would annually save society 65.6 million US
dollars and health care payers 61.1 million US dollars. In
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Canada it would annually save society 1.72 million CDN dol-
lars and the health care system 1.18 million CDN dollars (4).
Amongst several antiemetic agents, ondansetron is a
highly potent and selective serotonin 5-HT3 receptor an-
tagonist and has no worrisome adverse effects such as
drowsiness, extra pyramidal reactions, hallucination, con-
vulsion and neuroleptic malignant syndrome that may be
seen in other antiemetic medications. When ondansetron
is used for several clinical conditions related to vomiting
there is a very low risk of adverse effects (5, 6). A large num-
ber of studies have been done and have shown different re-
sults of success and failure in which oral ondansetron was
administered to assess the decrease rate of hospitalization
in children with diarrhea and vomiting (7-9). This study
was carried out to assess the effect of injective ondansetron
on decreasing the hospitalization rate in children with gas-
troenteritis and recurrent vomiting.
2. Methods
2.1. Setting
Patients between the age of six months and six years
were referred to Qods pediatrics academic hospital in
Qazvin city (west of Tehran, I.R. Iran). This hospital is a
state hospital under the supervision of Qazvin University
of Medical Sciences and it is a referral hospital. Children
with acute GE and recurrent vomiting were followed up for
their response to injective ondansetron and the possibil-
ity of treating them as outpatient cases. Meanwhile, other
cases in similar situations were selected as a control group
who did not receive ondansetron. Consent letters were ob-
tained from all parents prior to entering the study. This
study was approved by the Qazvin ethic committee.
2.2. Patients
Inclusion criteria: All individuals in both groups had
evidence of viral GE, recurrent vomiting was the only indi-
cation of referring them to hospital and the time of their
referral to the hospital was not more than 48 hours after
the beginning of the symptoms.
Exclusion criteria: Other cases with other causes (bac-
terial GE, protozoan GE, etc.), vomiting secondary to other
diseases and patients with symptoms prolonger than 48
hours were excluded. Considering a narrow duration
of symptoms was for having similar situations in both
groups.
The sample size was calculated through the following
formula:
(1)N =
2
(
Z1 − α2 + Z1−β
)2
P
(
1− P )
(P1−P 2)2
Considering P = (P1+P2)2 , P1 = 0.7, P2 = 0.5, α = 0.05
and β = 0.2 that yielded N = 96 (10).
2.3. Study Design
This study is a randomized controlled clinical trial
done for 200 patients with Gastroenteritis (GE) referred
to the Qods hospital from Feb 2014 to Jan 2015. Patients
recruited in this study randomly were assigned to two
groups based on Balanced Block Randomization. We have
6 blocks (AABB-BBAA-ABAB-BABA-BAAB-ABBA) that will ran-
domly be arranged. The control group received a rou-
tine plan (Metoclopramid) and the intervention group re-
ceived ondansetron. They are followed through hospital
reception documents and telephone calls until 72 hours af-
ter discharge. This follow up is to find out whether the pa-
tients have had any need to return to the hospital due to
recurrence of vomiting. All included cases of both groups
were treated with serums. The difference between the two
groups was receiving a dose of 0.15 mg/Kg ondansetron
through injection in study group. It should be noted
that some patients receive ondansetron routinely based
on their physician guidelines and others receive previous
drug regimes such as metoclopramid, ORS or other treat-
ments (registration ID in IRCT is IRCT2014090719077N1).
2.4. Primary Outcome
Our primary outcome was to find out whether the pa-
tients had any need to be returned to the hospital because
of recurrence of vomiting. However, all cases that did not
receive ondansetron were hospitalized as was routinely
done for years. All data of both groups including the rate
and duration of hospitalization were registered.
2.5. Statistical Analysis
We calculated the number and percentage of gender
and needing to admit which was analyzed by χ2 measure.
The duration of hospitalization was analyzed by mean ±
SD. The Mann-Whiteny program was used to compare the
hospitalization rate, age and duration of gastroenteritis
between two groups since the distribution of variables
were not normal. Furthermore, the ,duration of hospital-
ization was analyzed by the Cox-Regression model. Statis-
tical analysis was done by means of SPSS-version 19 and P
less than 0.05 was considered significant.
3. Results
In our study, of the 200 participated individuals in two
equal case and control groups, the mean age (year) was
2 Iran Red Crescent Med J. 2016; 18(11):e42907.
MahramM et al.
3.69± 2.61 and 3.16± 1.52, respectively. There were no sig-
nificant differences between them. Ninety percent of pa-
tients in the control group who were admitted were under
5 years old. However, 76 of the patients (76%) in the inter-
vention group with ondansetron were fewer than 5. Only
6% were admitted after receiving this drug.
Gender distribution included 44 girls and 56 boys in
the case group and 42 girls and 58 boys in the control
group. That did not show any significance (Table 1).
In the ondansetron group of people who received the
drug, 55% took only one dose and 45% needed the second
dose without observing any drug side effects.
Out of 100 individuals who received ondansetron (n =
91), 91% of cases did not need to be hospitalized or get rest
(n = 9) and 9 % needed to be admitted in the next 72 hours.
All 100 cases of the control group were hospitalized (P =
0.003) (Figure 1).
Vomiting in the control group of people who did not
receive ondansetron continued in 35 % after 72 hours of ad-
mission.
The duration of hospitalization for the patients of the
control group was 2.94± 1.40 days, amongst which the du-
rations compared with the case group (Table 2) from one
to six days were 16, 27, 24, 19, 8 and 6 %, respectively (Figure
2).
The Cox-Regression model showed that the age and
gender of patients did not have any significant effects
on the survival analysis; however, the leading complaints
such as fever, diarrhea and vomiting had the significant
confounder effect on it (Table 3).
4. Interpretation
The results of this study showed that 91% of infants
and children with diarrhea and vomiting who received on-
dansetron could be treated without hospitalization and as
outpatients, while only 9% were hospitalized. On the other
hand, the patients of the control group had a duration of
2.94± 1.40 days (range of one to six days) in the hospital
and repeating vomiting occurred in 35% of them. This high
percent of not hospitalized patients implies money, time
saved for the family and a lower load of admitted patients
for hospitals. These consequences are desirable in all as-
pects.
Most of the similar studies have shown the same re-
sults as ours, although a few differences in results could be
found. Golshekan et al. compared two groups of oral on-
dansetron and placebo in children with diarrhea and vom-
iting and found that 27% had persistent vomiting and 13.6%
were hospitalized in their 48 hour follow up (11). The re-
sults of a similar study by Roslund et al. showed that 21.6%
needed intravenous serum therapy after receiving oral on-
dansetron (12), which both showed higher rates of admis-
sion than ours. In a study on 1 to 14 year-old children,done
by Al-Ansari et al., it was found that after a single dose of
ondansetron, cessation of vomiting was achieved in 81% of
cases (13), which shows a lower rate of vomiting cessation
than ours. Das et al., through their review study, concluded
that oral and IV ondansetron significantly reduced the in-
cidence of hospitalization by 64% (RR: 0.36, 95% CI: 0.18,
0.72) and 79% (RR: 0.21, 95% CI: 0.05, 0.94) respectively (14).
This difference in the rout of ondansetron administration
is the reason of gaining a higher result in our study when
comparing similar studies in which the oral form of on-
dansetron was used. Other similar studies by Setayesh et
al. (8), Tabbah (15), Freedman et al. (14, 16), DeCamp et al.
(17), Gavagan et al. (18) and Mullarkey et al. (19) all showed
that ondansetron therapy decreases the risk of persistent
vomiting, the use of intravenous fluid and hospital ad-
missions in children with vomiting due to gastroenteri-
tis and/or its cost-effectiveness. In another study, results
showed after drug administration, 30 (81.1%) patients in the
ondansetron group did not experience vomiting as com-
pared to 9 (24.3%) patients of the placebo group (P < 0.01)
(20). In addition, children who received ondansetron were
less likely to vomit not only during the first 8 hour follow-
up in the emergency department [relative risk (RR): 0.33,
95% CI: 0.19 - 0.56,] but also during the next 24 hour follow-
up (RR: 0.15, 95% CI: 0.07 - 0.33) (21).
Despite these studies in agreement with administra-
tion of ondansetron and its effectiveness, some other stud-
ies point to its effect on prolongation of diarrhea duration
due to fluid and toxin retention. The UK guideline deter-
mined that ondansetron prolongs the QT interval in a dose-
dependent manner; therefore, it should be avoided in peo-
ple with congenital long QT syndrome. Doctors should
pay more attention to some patients such as those with
electrolyte abnormalities, congestive heart failure, brad-
yarrhythmias and so on (22). Another study declared that
although ondansetron is a widely accepted treatment for
GE in children, a broader spectrum of primary diagnoses
such as non GE, otitis media, diabetes and pneumonia for
which ondansetron is being used should be considered
(23).
4.1. Limitation and Strength
The limitation of this study was the absence of the pro-
longed follow-up of the patients in the ondansetron group
to find out the probable effect of the drug on the duration
of diarrhea. This was not included in our study targets.
Suggestions for future studies consist of assessment of on-
dansetron effects on severity and duration of diarrhea, es-
pecially with regards to its etiology and cost-effectiveness
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Table 1. Demographic Variables in Two Groups of Study (Intervention with Ondansetron and Control Group)
Group Age, Mean± SD
Duration of
Gastroenteritis,
Mean± SD
Duration of
Hospitalized,
Mean± SD
Gender Chief Complaint
Female, No. (%) Male, No. (%) Recurrent
Vomiting, No.
(%)
Fever, No. (%)a
Control, N = 100 3.16± 1.52 1.34± 0.48 2.94± 1.41 42 (42) 58 (58) 80 (80) 20 (20)
Case, N = 100 3.69± 2.61 1.07± 0.26 0.11± 0.37 44 (44) 56 (56) 75 (75) 25 (25)
Z = -0.207 Z = -4.717 Z = -12.592 X2 = 0.082 X2 = 0.717
P value 0.836 < 0.001 < 0.001 0.775 0.397
aDiarrhea and vomiting.
  Unnecessary 
to hospitalized, 
N = 0 
Recruitment (n = 200)
 Case group, receive 
ondansetron, N = 100 
 Control group, not receive 
ondansetron, N = 100 
Necessary to 
hospitalized,  
N = 100 
Hospitalized, 
N = 9
Unnecessary to
hospitalized, N = 91
Figure 1. Profile of Participants in Two Groups of Study
of administration the drug, which can be different from
one community to another.
4.2. Conclusion
The main conclusion of the current study is the em-
phasis on administrating ondansetron, which can lead to
a decreased rate of hospitalization in infants and children
with diarrhea and recurrent vomiting. Also, when compar-
ing similar studies on using the oral form of the drug it
showed that it had a better result when the injective form
was used.
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Table 2. Means and 95% Confidence Interval for Survival Time of Two Groups
Group Mean Log Rank (Mantel-Cox)
Estimate Std. Error 95% Confidence Interval Chi-Square P Value
Lower Bound Upper Bound
Control 2.940 0.141 2.664 3.216 22.579 0.001
Case 1.222 0.147 0.934 1.510
Overall 2.798 0.137 2.529 3.067
Table 3. β and SE of Chief Complaint Variable in the Equation of of Cox-Regression Model Based on Forward- LR.
Non- Equation Score Sig. Equation B SE Sig. Exp (B)
Age 0.057 0.811 Step 1 Group -1.443 0.378 < 0.001 0.236
Gender 0.479 0.489 Step 2 Chief complaint -.573 0.249 0.021 0.564
Chief complaint 5.677 0.017 Group -1.415 0.376 < 0.001 0.243
Group 17.201 < 0.001
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Figure 2. Plot of Survival Function in Two Groups Based on the Cox-Regression
Model
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